量化非选择性β受体阻滞剂预防肝功能失代偿的获益:PREDESCI试验的贝叶斯再分析
本研究对PREDESCI试验进行贝叶斯再分析,纳入三种先验(中性、乐观、悲观),评估β受体阻滞剂降低全因失代偿的概率与获益幅度;结果显示所有先验下概率均>0.93,后验HR从0.50到0.70,微模拟显示10年无失代偿生存年显著增加。
要点
- 贝叶斯再分析显示β受体阻滞剂降低全因失代偿的概率在所有先验下均>0.93。
- 后验HR范围0.50(乐观先验,95%可信区间0.27-0.93)至0.70(中性先验,95%可信区间0.44-1.12)。
- 微模拟显示中性先验下10年每1000例患者增加497个无失代偿生存年。
核心结论
- β受体阻滞剂治疗与高概率的临床获益相关,可能在人群水平上转化为无失代偿生存年的大幅增加。
研究设计与样本
- 对PREDESCI试验的贝叶斯再分析,纳入三种先验:中性、乐观和悲观先验。
主要发现
- 在贝叶斯分析中,所有先验下β受体阻滞剂降低全因失代偿的概率均>0.93。
- 全因失代偿的贝叶斯后验风险比(HR)范围为0.50(乐观先验,95%可信区间0.27-0.93)至0.70(中性先验,95%可信区间0.44-1.12)。
- 采用中性先验后验HR和5%年失代偿发生率,10年时每1000例患者平均增加497个无失代偿生存年。
- 采用乐观先验后验HR和10%失代偿发生率,10年时每1000例患者增加1639个无失代偿生存年。
关键数值与推荐
- 所有先验下β受体阻滞剂降低全因失代偿的概率>0.93。
- 后验HR:乐观先验0.50(95%可信区间0.27-0.93);中性先验0.70(95%可信区间0.44-1.12)。
- 中性先验后验HR和5%年失代偿发生率下,10年每1000例患者增加497个无失代偿生存年。
- 乐观先验后验HR和10%失代偿发生率下,10年每1000例患者增加1639个无失代偿生存年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Beta-blockers have been studied for the prevention of variceal bleeding and, more recently, for the prevention of all-cause decompensation. Some uncertainties regarding the benefit of beta-blockers for the prevention of decompensation remain. Bayesian analyses enhance the interpretation of trials. The purpose of this study was to provide clinically meaningful estimates of both the probability and magnitude of the benefit of beta-blocker treatment across a range of patient types. APPROACH AND RESULTS: We undertook a Bayesian reanalysis of PREDESCI incorporating 3 priors (moderate neutral, moderate optimistic, and weak pessimistic). The probability of clinical benefit was assessed considering the prevention of all-cause decompensation. Microsimulation analyses were done to determine the magnitude of the benefit. In the Bayesian analysis, the probability that beta-blockers reduce all-cause decompensation was >0.93 for all priors. The Bayesian posterior hazard ratios (HR) for decompensation ranged from 0.50 (optimistic prior, 95% credible interval 0.27-0.93) to 0.70 (neutral prior, 95% credible interval 0.44-1.12). Exploring the benefit of treatment using microsimulation highlights substantial treatment benefits. For the neutral prior derived posterior HR and a 5% annual incidence of decompensation, at 10 years, an average of 497 decompensation-free years per 1000 patients were gained with treatment. In contrast, at 10 years 1639 years per 1000 patients were gained from the optimistic prior derived posterior HR and a 10% incidence of decompensation. CONCLUSIONS: Beta-blocker treatment is associated with a high probability of clinical benefit. This likely translates to a substantial gain in decompensation-free life years at the population level.
引用
- Rowe IA, Villanueva C, Shearer JE, et al. Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial. Hepatology. 2023. PMID: 36897269. doi:10.1097/HEP.0000000000000342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。